(6-(Trifluoromethyl)pyridin-2-yl)boronic acid, 95.0%, 1g

4-amino-1-methylpyrrolidin-2-one, 95.0%, 1g

1-Benzyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid, 97.0%, 1g

(3R,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diol, 98.00%, 500g

2-Methyl-1-prop-2-ynyl-1H-indole-3-carbaldehyde, 95.0%, 250mg

5-HYDROXY-7-METHOXY-2-METHYL-4H-CHROMEN-4-ONE, 95.0%, 25mg

Pyrimidine-5-carbothioamide, 95.0%, 100mg

Methyl 2-bromo-3-[4-(trifluoromethoxy)phenyl]-propionate, 98.0%, 5g

Microliter syringe GASTIGHT® series 1700 Point type 3, 500 µl, 1750 RNR, 1 piece

5-[(methylthio)methyl]-1H-tetrazole, 95.0%, 25g

TERT-BUTYL 4-(1H-INDOL-1-YL)PIPERIDINE-1-CARBOXYLATE, 95.0%, 250mg

1-(2-Amino-acetyl)-piperidine-4-carboxylic acidethyl ester hydrochloride, 98.0%, 1g

(E)-3-(5-Fluoropyridin-2-yl)-2-propenoic acid hydrochloride, 95%, 1g